| TTM
|
11/30/2025
|
11/30/2024
|
11/30/2023
|
11/30/2022
|
|
|---|---|---|---|---|---|
| Total Revenue
|
0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
|
0 | -- | 0 | -14.5090 | -23.9770 |
|
Gross Profit
|
0 | -- | 0 | -14.5090 | -23.9770 |
| Selling, General and Administrative Expenses
|
-3,550.2370 | -4,113.2750 | -701.3750 | -510.0320 | -242.8270 |
|
Research and Development Expenses
|
-180.9920 | -180.0920 | -83.7500 | 0 | -- |
| Depreciation, Amortization and Depletion
|
-2.0860 | -2.0860 | -2.2810 | -18.4710 | -19.1590 |
|
Operating Income/Expenses
|
-3,747.9970 | -4,295.4530 | -787.4060 | -528.5030 | -261.9860 |
|
Total Operating Profit/Loss
|
-3,747.9970 | -4,295.4530 | -787.4060 | -543.0120 | -285.9630 |
| Irregular Income/Expenses
|
0 | 0 | -26.5050 | -42.3570 | 0 |
|
Other Income/Expense, Non-Operating
|
0 | 0 | 3.4730 | 3.6080 | 1.7800 |
|
Non-Operating Income/Expenses, Total
|
0 | 0 | -23.0320 | -38.7490 | 1.7800 |
|
Pretax Income
|
-3,747.9970 | -4,295.4530 | -810.4380 | -581.7610 | -284.1830 |
|
Net Income from Continuing Operations
|
-3,747.9970 | -4,295.4530 | -810.4380 | -581.7610 | -284.1830 |
|
Net Income after Extraordinary Items and Discontinued Operations
|
-3,747.9970 | -4,295.4530 | -810.4380 | -581.7610 | -284.1830 |
|
Net Income after Non-Controlling/Minority Interests
|
-3,747.9970 | -4,295.4530 | -810.4380 | -581.7610 | -284.1830 |
|
Net Income Available to Common Stockholders
|
-3,747.9970 | -4,295.4530 | -810.4380 | -581.7610 | -284.1830 |
|
Diluted Net Income Available to Common Stockholders
|
-3,747.9970 | -4,295.4530 | -810.4380 | -581.7610 | -284.1830 |
| Basic EPS
|
-0.18 | -0.23 | -0.06 | -0.06 | -0.04 |
| Diluted EPS
|
-0.18 | -0.23 | -0.06 | -0.06 | -0.04 |
|
Basic Weighted Average Shares Outstanding
|
22,116.5040 | 18,968.3600 | 12,725.7820 | 10,339.6030 | 9,176.6320 |
|
Diluted Weighted Average Shares Outstanding
|
22,116.5040 | 18,968.3600 | 12,725.7820 | 10,339.6030 | 9,176.6320 |
| Income Statement, Supplemental
|
|||||
|
EBIT
|
-3,747.9970 | -4,295.4530 | -810.4380 | -581.7610 | -284.1830 |
|
EBITDA
|
-3,731.2290 | -4,293.3670 | -808.1570 | -563.2900 | -265.0240 |
|
Normalized EBITDA
|
-3,569.1960 | -3,242.6670 | -781.6520 | -242.1210 | -265.0240 |
|
Normalized Income
|
-3,585.9640 | -3,244.7530 | -783.9330 | -260.5920 | -284.1830 |
|
Total Unusual Items
|
162.0330 | 1,050.7000 | 26.5050 | 321.1690 | 0 |
|
Total Unusual Items Excluding Goodwill
|
162.0330 | 1,050.7000 | 26.5050 | 321.1690 | 0 |
|
Tax Effect of Unusual Items
|
0 | 0 | 0 | 0 | 0 |
|
Tax Rate, Calculated
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
11/30/2022 - 8/3/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade